To evaluate the pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease.
Analyzed pharmacokinetic data of vonoprazan in a pediatric population.
Compared exposure levels between adolescents, children, and adults.
Assessed safety and tolerability of standard doses.
Vonoprazan exposure in adolescents and children mirrored that found in adults.
Both 10 mg and 20 mg doses were deemed appropriate for pediatric use.
Safety profiles were consistent with adult findings.
Abstract
Exposures of vonoprazan in adolescents and children were nearly identical to exposures observed in adults, confirming the appropriateness of vonoprazan 10 and 20 mg doses in a pediatric population.